Literature DB >> 10586622

[Clinicopathological characteristics of Creutzfeldt-Jakob disease with a PrP V180I mutation and M129V polymorphism on different alleles].

Y Iwaski1, M Sone, T Kato, E Yoshida, T Indo, M Yoshida, Y Hashizume, M Yamada.   

Abstract

We report an 80-year-old Japanese man with histologically-diagnosed Creutzfeldt-Jakob disease (CJD). The patient was admitted to our neurological unit because of sudden onset motor aphasia-like symptoms and right hemiparesis. His medical and family histories were unremarkable, and he had taken no medications. Urine, blood counts and blood chemistry were all within normal limits. Cerebrospinal fluid was normal except for elevation of neuron specific enolase (29.9 ng/ml). High-signal intensity was demonstrated in the cortex of the left temporal lobe on T2-weighted MRI images, and the lesion swelled during the initial stage of the disease. There was no enhancement with Gd-DTPA. Serial MRI showed that the high-signal lesion had spread into the bilateral cerebral cortex. The patient developed myoclonus followed by akinetic mutism within 6 months of onset. Consecutive EEGs revealed no periodic synchronous discharge (PSD). He died of pneumonia 21 months after of admission. Autopsy revealed spongiform changes in the cerebral cortex with Kuru plaques, confirming the diagnosis of CJD. The Cerebellar cortex was well preserved. The high-signal lesions corresponded to the spongiform changes in the cerebral cortex. Immunohistochemical analysis showed weak synaptic prion staining. Prion protein (PrP) gene analysis of genomic DNA isolated from the autopsied brain by polymerase chain reaction, the restriction fragment length polymorphisms, and direct sequencing revealed a point mutation (Val-->Ile) at codon 180 and a polymorphism (Met/Val) at codon 129 on different alleles. A few CJD patients with point mutations in codon 180 of the PrP gene have been reported. Combination of the codon 180 point mutation and codon 129 polymorphism may yield an atypical clinicopathological form of CJD that includes late onset, negative PSD, and atypical MRI findings, with preservation of the cerebellar cortex.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586622

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  5 in total

1.  Pathological progression of genetic Creutzfeldt-Jakob disease with a PrP V180I mutation.

Authors:  Akio Akagi; Yasushi Iwasaki; Maya Mimuro; Tetsuyuki Kitamoto; Masahito Yamada; Mari Yoshida
Journal:  Prion       Date:  2018-01-31       Impact factor: 3.931

2.  Familial Creutzfeldt-Jakob disease with a V180I mutation: comparative analysis with pathological findings and diffusion-weighted images.

Authors:  Kazuo Mutsukura; Katsuya Satoh; Susumu Shirabe; Itsuro Tomita; Takayasu Fukutome; Minoru Morikawa; Masachika Iseki; Kensuke Sasaki; Yusei Shiaga; Tetsuyuki Kitamoto; Katsumi Eguchi
Journal:  Dement Geriatr Cogn Disord       Date:  2009-12-30       Impact factor: 2.959

3.  Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies.

Authors:  Anna Ladogana; Pascual Sanchez-Juan; Eva Mitrová; Alison Green; Natividad Cuadrado-Corrales; Raquel Sánchez-Valle; Silvia Koscova; Adriano Aguzzi; Theodoros Sklaviadis; Jerzy Kulczycki; Joanna Gawinecka; Albert Saiz; Miguel Calero; Cornelia M van Duijn; Maurizio Pocchiari; Richard Knight; Inga Zerr
Journal:  J Neurol       Date:  2009-05-15       Impact factor: 4.849

4.  A case of V180I genetic Creutzfeldt-Jakob disease presenting with conspicuous facial mimicry.

Authors:  Yasushi Iwasaki; Keiko Mori; Masumi Ito; Yoshinari Kawai
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

5.  Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease.

Authors:  Yuichi Hayashi; Yasushi Iwasaki; Masahiro Waza; Shinei Kato; Akio Akagi; Akio Kimura; Takashi Inuzuka; Katsuya Satoh; Tetsuyuki Kitamoto; Mari Yoshida; Takayoshi Shimohata
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.